Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Nov 4;19(11):e0310372. doi: 10.1371/journal.pone.0310372

Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic area

Francois Kiemde 1,*, Hermann Sorgho 1, Serge Henri Zango 1, Gnohion Fabrice Some 1, Toussaint Rouamba 1, Ousmane Traore 1, Berenger Kabore 1, Hamtandi Magloire Natama 1, Yeri Esther Hien 2, Innocent Valea 1, Henk Schallig 3, Halidou Tinto 1
Editor: Ibrahim Sebutu Bello4
PMCID: PMC11534236  PMID: 39495748

Abstract

Background

The hormonal shift occurring in pregnant women is crucial for the outcome of pregnancy. We conducted a study in pregnant women living in a malaria endemic area to determine the potential effect of gestational age on the modulation of the endocrine system by cortisol and prolactin production during pregnancy.

Methods

Primigravidae and multigravidae with a gestational age between 16–20 weeks were included in the study and followed up to delivery and 6–7 weeks thereafter. Venous blood was collected at scheduled visit: Visit 1 (V1; 16–20 weeks of amenorrhea), Visit 2 (V2; 28 ±1 weeks of pregnancy), Visit 3 (V3; 32 ±1 weeks of pregnancy), Visit4 (V4; delivery) and Visit5 (V5; 6–7 weeks after delivery). In addition, a cord blood sample was also collected during labour at delivery. Nulliparous and primiparous/multiparous non-pregnant women were enrolled in the control group. Cortisol and prolactin plasma concentrations were measured using ichroma II and i-chamber apparatus. Light microscopy was used to detect Plasmodium falciparum infections. A linear mixed-effects regression (LMER) model was used to assess the association between the variation of cortisol titres and prolactin levels during the pregnancy and the post-partum.

Results

Results showed that cortisol and prolactin levels in the peripheral blood were globally up-regulated during pregnancy. Concentrations of cortisol during follow-up was significantly higher in primigravidae than in multigravidae during the whole pregnancy (p<0.024). Moreover, the level of prolactin which was higher before delivery in primigravidae reversed at delivery and postpartum visit, but the difference was not statistically significant during the follow-up (V1 to V5) (p = 0.60). The cortisol level in peripheral blood at delivery was higher than that in the cord blood, and conversely for prolactin. Cortisol and prolactin levels decreased after delivery, though the level of prolactin was still higher than that at enrolment. An increase of one unit of prolactin was associated with the decrease of the average concentration of cortisol by 0.04 ng/ml (p = 0.009). However, when cortisol increases with one unit, the average concentration of prolactin decreases by 1.16 ng/ml (p = 0.013).

Conclusion

These results showed that the up-regulation effects of cortisol and prolactin are related to gestational age. A The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) was also reported.

1. Background

The maternal immune system plays an important role in the protection of the mother against environmental pathogens and to prevent the developing foetus against any damage [18]. The immunological variation of the mother during pregnancy is crucial in the outcome of pregnancy. However, in sub-Saharan Africa (SSA), some infections during pregnancy, like malaria, lead to complications. These complications lead to important burden for both mothers and their new-borns and thus represent a real public health concern, in particular among women experiencing their first or second pregnancy [9].

For many years, the focus on the concept of immunology of pregnancy as an organ transplant has complexified research in the field of immunity development during pregnancy and delayed the development of new pathways with clinical implications that could help to answer the existing gaps and other relevant questions [10]. Among these gaps and relevant question, the "suppression of (some) immune responses" concept ranks among those that have been accepted by all [11]. This concept was supported by the idea that the maternal immune response is biased towards humoral immunity [12], which could explain the suppression of immune retaliation against the developing foetus. Studies consider immunosuppression as a state in which immune system does not work as well it should. This mechanism provided to mother an effective protection from harmful pathogens while allowing tolerance to foetal antigens [13, 14]. However, several studies have shown that the development of the placenta changes and adapts the immune system to pregnancy without suppressing it [15]. This testifies the capacity of pregnant women to develop immune responses when the mother and/or the foetus are threatened [1, 2]. However, this association between the foetus and the immune system of the pregnant woman supports the hypothesis that the (hormonal) changes made during pregnancy and the adaptation of the immune system to pregnancy could depend on gestation (number of pregnancies).

Pregnancy is marked by a complex interplay of hormonal shifts, with cortisol and prolactin being two of the pivotal hormones regulating various maternal and foetal processes [16]. Cortisol, a glucocorticoid produced by the adrenal cortex, plays a crucial role in metabolic functions, stress responses, and the maturation of foetal organs [17]. Prolactin, secreted by the anterior pituitary, not only prepares the body for breastfeeding but also modulates the maternal immune system and foeto-maternal interface [18]. The hormonal changes that occur during pregnancy contribute significantly to immunological changes [19, 20]. This is the case of stress responses on immune system during pregnancy. Indeed, the immune stress can be bidirectional by enhancing or suppress immune function [21, 22]. Cortisol and prolactin are among the hormones whose concentrations vary during pregnancy [23, 24]. The relationship between these hormones and the immune system has been demonstrated [25]. Cortisol acts as an immunosuppressive hormone [26, 27], whereas prolactin functions as an immunostimulatory hormone [2830]. Although several studies reported the association between cortisol and prolactin levels with malaria in pregnancy [3133], very few studies have investigated the evolution of cortisol and prolactin concentrations according to the stage and age of gestation [34]. In such context, more studies are needed to better understand the dynamic of cortisol and prolactin in peripheral blood during pregnancy and in umbilical cord blood at delivery. This could contribute to adapt prevention strategies against infectious diseases, especially in malaria endemic settings. The present study was designed to investigate the potential effect of gestation in modulating cortisol and prolactin levels in peripheral blood samples during pregnancy and in cord blood at delivery in a malaria endemic area.

2. Methods

Study site

The study was conducted in the health district of Nanoro, located in the Center-West region of Burkina Faso. Nanoro is situated approximately 85 km away from Ouagadougou, the capital city. Malaria, caused by Plasmodium falciparum, remains the first cause of medical consultation in pregnant women in this region and predominately occurs during the rainy season July-November which overlap with the peak of malaria transmission.

Participants were enrolled in three (03) peripheral health facilities of the district (Nanoro, Nazoanga and Seguedin) where biological samples were collected and transported to the central laboratory of the Clinical Research Unit of Nanoro (CRUN) for processing and storage.

Study design

This was a cohort study (2 cohorts), comprising prolactin and cortisol variation during pregnancy in primigravidae and multigravidae women. Non pregnant nulliparous and primiparous/multiparous were also enrolled in this study as control group and sampling once during the study for cortisol and prolactin titter. Pregnant women (primigravidae and multigravidae) attending the antenatal consultation (ANC) at one of the participating health facilities with fundal height less than 20 cm were invited to participate to the study. Written informed consent was obtained from each participant prior to the samples and data collection. Gestational age was determined by ultrasound and only participants with a pregnancy aged between 16 to 20 weeks were enrolled and followed-up until delivery and 6–7 weeks thereafter. During the follow-up, venous blood was collected in EDTA (Ethylene diamine tetra acetic acid) tube at the following timepoints:16th-20th weeks of pregnancy (V1); 28th±1 week of pregnancy (V2), 32th±1 week of pregnancy (V3), delivery (V4) and 6th-7th weeks after delivery (V5). Regarding the rationale behind these time points, the choice of 16th to 20th weeks of pregnancy is related to the fact that pregnant women consult to their first antenatal consultation at this period, due to socio-economic factors. This also represent the end of organogenesis. The choices of 28th±1 weeks of pregnancy is related to the maturation of the different organs of the foetus and 32th±1 to the pre-delivery. A cord blood sample was also collected at delivery. Pregnant women were encouraged to deliver at the participating health facilities to receive adequate care and facilitate the collection of blood samples (venous blood during the labour and umbilical cord blood at delivery).

For the control groups, participants were recruitment within the catchment area of the recruitment health facilities listed above. In this group, participants included were non-pregnant nulliparous and both primiparous/ multiparous individuals. The number of nulliparous and primiparous/ multiparous to be recruited by health facility catchment area were paired respectively to the number of primigravidae and multigravidae women recruited in this health facility catchment area. For each participant enrolled in the control group, venous blood was drawn once into EDTA tubes. Written informed consent was also signed by each non-pregnant women before data collection. No follow-up visit was performed for this group. To ensure that control participants were not pregnant, an immunologic pregnancy test (IPT) was performed and only women with negative IPT were enrolled in the control arm. Those for whom the IPT turned positive were referred to the maternity for appropriate care. Enrolment was carried out from July to November 2018 for pregnant women and from April to July 2019 for non-pregnant women.

Operational definition

  • Primigravidae women refer to women who were pregnant for the first time;

  • Multigravidae women refer to women who were pregnant more than one time;

  • Nulliparous women refer to women who were never give birth;

  • Primiparous/multiparous women refer to women who already gave birth at least one time.

Ethical consideration

This study was approved by the institutional ethics committee of Centre Muraz of Bobo Dioulasso, Burkina Faso (N/Réf 000013 of 24 March 2015).

Laboratory procedure

Blood samples collection and transport

The blood samples collected in this study were consisted of maternal venous blood collected at each scheduled visit including delivery (during labour) and umbilical cord blood. The blood samples were collected in EDTA tube. Only 3 ml of blood (venous or umbilical cord) was collected. The blood samples were immediately transported to the clinical laboratory of CRUN under cool condition (+4°C). Pregnant women were encouraged to give birth at the health center in order to receive more adequate health care and to facilitate the sampling of venous blood during labour and umbilical cord blood after delivery. The umbilical cord blood was collected after clamping the umbilical cord at 2.5 cm above its foetal insertion.

For non-pregnant women, a single blood (venous) sample was taken after a negative IPT.

Biochemical test of cortisol and prolactin

Plasma samples were obtained by centrifuged the EDTA tubes at 2,000G for 10 minutes to separate the pellet from the plasma. All plasma were collected in labelled sterile tubes and then stored at -20°C until its used for biochemical testing within the 30 days.

Plasma concentrations of cortisol and prolactin were determined by using the test device ichromaTM cortisol for the quantification of cortisol and ichromaTM prolactin for the quantification of prolactin on the devices i-chamber (Weldon Biotech India Pvt. Ltd. India) and ichroma II (Boditech Med Inc. Korea) according to the procedure described by the manufacturer. For the quantification of the cortisol, 30μl of plasma were transferred to the tube containing the detection buffer provided by the manufacturer and mixed 10 times manually by pipetting. A volume of 75μl of the mixture were placed in the well of the ichromaTM cortisol cartridge and immediately incubated at 25°C for 10 minutes in the i-chamber. After incubation, the cartridge was removed and read immediately in the ichroma II. The analyzer automatically displayed the test result on the display screen, printed and validated. The procedure of quantification of prolactin was similar to cortisol, except the volume of plasma pipetted (75μl instead of 30μl).

The threshold for prolactin quantification with ichroma II is 100ng/ml. In case of concentration over 100ng/ml, ¼ and 18 dilution of the plasma was done with saline phosphate buffer as recommended by the manufacturer. The exact value of the prolactin was then obtained by multiplying the measured value by the dilution factor.

Malaria microscopy

Malaria diagnosis by microscopy was performed by expert microscopists at CRUN central laboratory. Thick and thin blood smears were prepared (in duplicate) from venous blood collected in EDTA tubes. Thin films were fixed with methanol and blood slides were stained with 10% Giemsa solution for identification and quantification of asexual Plasmodium falciparum and other Plasmodium species. Parasite density was determined in thick blood smear by counting the number of asexual parasites per 200 leucocytes and estimated per μl of blood, based on an assumed white blood cells of 8,000 per μl by light microscopy. Thick blood smear was considered negative when the examination of 100 thick film fields did not reveal the presence of any asexual parasites. Each blood slide was read by two independent readers, and in case of discrepancy (positive versus negative, difference in Plasmodium species, difference in parasite density >Log10 or ratio>2 in case of parasite density ≤400/μl and >400/μl respectively) the blood slide was read again by a third independent reader whose conclusion was decisive. Positive microscopy results were recorded as the geometric means of the results from both readers results or the geometric means of the two geometrically closest reading in case of third reading. These results were expressed as asexual parasites per microliter by using the patient’s white blood cell (WBC) count. A selection of slides (5%) was re-read by an independent expert microscopist for quality control.

Sample size and data analysis

This study is part of a study that aimed to determine the cytotoxicity of Natural Killer (NK) cells against erythrocytes infected by Plasmodium falciparum. The sample size was determined in the framework of the NK cells cytotoxicity study. Briefly, the samples size was determined by considering the cytotoxicity of NK cells. Considering the results reported by Mavoungou et al. 2003, we estimated a standard deviation (SD) = 0.29, the effect size (EF) = 0.51, α = 0.05, number of groups = 4, using on F test with power = 0.8, our sample size was 48. By considering 10% of non-response (miss of follow-up), the sample size was estimated at 48 + 4 = 52 participants, meaning 13 women for each cohort (primigravidae and multigravidae) and 13 women per control group (nulliparous and primiparus/multiparous).

Data were collected on paper case report forms (CRF) and subsequently entered using REDCap (Research Electronic Data Capture) software.

The data analysis was done by using R software (R Foundation for Statistical Computing, Vienna, Austria). Description of qualitative and quantitative variables were performed by using proportion and mean ± SD (or median with IQR where appropriate), respectively. For the comparison cortisol and prolactin concentrations between gravity, the Wilcoxon rank-sum test was used. A repeated measure ANOVA test was used to compare the log value of cortisol and prolactin between the visits.

To assess the association between the overall change of cortisol and prolactin, we used a linear mixed-effects regression (LMER) model, which accounts for both fixed-effect factors and random-effect factor (subject and visit). The fixed-effect factors included in the LMR was gravidity, parasitaemia and cortisol (if the outcome variable is prolactin) or prolactin (if the outcome variable is cortisol). A p value <0.05 was considered as statistically significant.

3. Results

Characteristic of the study population

The basic characteristics of study population are presented on Table 1. A total of 56 pregnant women with fundal height less than 20 cm were screened and 50% (28/56) with gestational age between 16th-20th weeks (13 primigravidae and 15 multigravidae) were enrolled for the follow-up. The per-protocol (PP) population included 24 pregnant women (12 primigravidae and 12 multigravidae): 2 multigravidaes were loss of follow-up, 1 multigravidaes has delivered outside the study area and 1 primigavidae was dead. In total, 23 women were delivered vaginally and a primigravidae by caesarean. For non-pregnant women 27 (15 nulliparous and 12 primiparous/multiparous) were enrolled.

Table 1. Characteristic of study population.

Pregnant women Non-pregnant women
Parameters Primigravidae Multigravidae Nulliparous Primiparous/ Multiparous
Age (years) (SD) 18.9 (2,5) 25.8 (5.4) 18.9 (2.0) 34.1 (4.7)
Gestational age (weeks) [IQR] 17.6 [16.4–18.4] 17.6 [16.9–18.0] - -
Malaria diagnosis (microscopy), n (%) 3 (20.0) 0 (0)
    V1 (16–20 weeks) 10 (76.9) 5 (38.5) - -
    V2 (28±1 weeks) 1 (7.7) 1 (7.7) - -
    V3 (32±1 weeks) 2 (15.4) 0 (0) - -
    V4 (delivery) 0 (0) 2* (15.4) - -
    V5 (6–7 weeks after delivery) 1 (7.7) 1 (7.7) - -

*1 microscopy was positive for cord blood.

Table 1 summarize the characteristic of study population. Globally malaria was mostly diagnosed at enrolment and could be due to the fact that most of them were at their first antenatal visit and were not under IPTp.

In the pregnant women group, the mean age was 18.9 years (Standard deviations (SD): 2.5) in primigravidae cohort versus 25.8 years (SD: 5.4) in multigravidae cohort. Gestational age was 17.6 weeks (interquartile range (IQR): 16.4–18.4) for primigravidae and 17.6 weeks (IQR: 16.9–18.0) for multigravidae. In the non-pregnant women group, the mean age was 18.9 years (SD: 2.0) and 34.1 years (SD: 4.7) for nulliparous and primiparous/multiparous, respectively.

Variation of cortisol during pregnancy

A gradual increase in cortisol concentrations from the enrolment to delivery was observed (primigravidae 99.2 ng/ml [86.4–130.1]; multigravidae 94.4 ng/ml [85.9–134.5]), with a decrease between V2 (primigravidae 127.7 ng/ml [111.7–134.4]; multigravidae 116.4 ng/ml [98.8–124.2]) and V3 (primigravidae 108.2 ng/ml [97.6–124.5]; multigravidae 107.6 ng/ml [100.2–119.1]), and the highest concentrations measured at delivery (primigravidae 173.0.2ng/ml [160.0–194.0]; multigravidae 128.3 ng/ml [118.8–174.7]). These concentrations however decreased at 6–7 weeks postpartum reaching 79.3 ng/ml [50.4–96.5] for primigravidae and 59.2 ng/ml [47.1–88.2] for multigravidae. Primigravidae showed a higher increase of cortisol than multigravidae during pregnancy with statistically significant different (p = 0.033). This increase of cortisol concentration across visits was statistically significant from 32th±1 weeks of pregnancy (primigravidae: median 108.2 ng/ml [97.6–124.5]; multigravidae 107.6 ng/ml [100.2–119.1]) until delivery (p<0.001) (see Fig 1 and S1 Table).

Fig 1. Dynamics of cortisol levels measured in pregnant women during pregnancy determined at different ANC visits.

Fig 1

Legend: NS: not significant; V: visit. Code: *: <0.05; **: <0.01; ***: <0.001; ****: <0.0001. In each case, 30μl of plasma was used to determine for cortisol level in blood (ng/ml). Cortisol levels were compared between multigravidae and primigravidae at each scheduled visits and presented as box and whisker plots illustration: top, bottom and middle of box, representing 25th, 75th and 50th percentiles, respectively. In both group, cortisol concentration increased in a sawtooth pattern during pregnancy with peaks at V2(28th±1 week) and V4 32th ±1 week), before decreasing at V5 which is part of post-partum.

At delivery, peripheral blood cortisol concentration measured during labour (162.9 ng/ml [127.3–190.5]) was higher than the concentration in umbilical cord blood (143.5 ng/ml [119.2–179.6]), but the difference was not statistically significant (p = 0.158) (Table 2). However, when stratified by gravidity, cortisol level comparison showed a statistically significant difference in umbilical cord blood only (primigravidae 170.0n g/ml [148.0–187.9]; multigravidae 119.2 ng/ml [64.8–147.6]; p = 0.019) (Table 3).

Table 2. Cortisol and prolactin concentration in peripheral blood and umbilical cord blood at delivery.

Babies Mothers Overall P-value
Prolactin (ng/ml) [IQR] 529.0 [386.3–712.7] 324.6 [206.6–375.2] 256.9 [16.1–461.9] 0.001
Cortisol (ng/ml) [IQR] 143.5 [119.2–179.6] 162.9 [127.3–190.5] 124.4 [89.8–170.0] 0.158

Table 2 summarize the concentration of prolactin and cortisol in babies and mothers at delivery. The difference was statistically different for prolactin but not for cortisol.

Table 3. Stratification of cortisol and prolactin concentration by gravidity in peripheral blood and umbilical blood at delivery.

Primigravidae Multigravidae Overall P-value
Peripheral blood Prolactin (ng/ml) [IQR] 269.2 [181.2–346.9] 364.7 [261.5–436.9] 324.6 [206.6–375.2] 0.160
Cortisol (ng/ml) [IQR] 172.7 [159.9–190.5] 135.0 [119.0–181.4] 162.9 [127.3–190.5] 0.143
Umbilical blood Prolactin (ng/ml) [IQR] 543.7 [386.3–853.1] 510.2 [410.2–566.4] 529.0 [386.3–712.7] 0.529
Cortisol (ng/ml) [IQR] 170.0 [148.0–187.9] 119.2 [64.8–147.6] 143.5 [119.2, 179.6] 0.019

Table 3 summarize the stratification of prolactin and cortisol by gravidity. The difference was only statistically different for cortisol of umbilic blood.

Variation of prolactin during pregnancy

A progressive increase of prolactin concentrations was also observed from inclusion (primigravidae 88.9 ng/ml [71.5.0–126.7]; multigravidae 33.9 ng/ml [30.4–74.8]) to delivery (primigravidae 269.2ng/ml [170.0–353.7]; multigravidae 368.0 ng/ml [266.0–565.0]). The concentration of prolactin was higher in primigravidae than multigravidae at baseline (visit 1) to visit 3 (primigravidae 334.3 ng/ml [226.0–420.5]; multigravidae 251.0 ng/ml [234.0–326.0]). The concentration of prolactin decreased from delivery to 6–7 weeks after delivery for primigravidae and multigravidae but remained higher in multigravidae than primigravidae. Nevertheless, the difference was not statistically significant during the follow-up (p = 0.58) (see Fig 2 and S1 Table).

Fig 2. Dynamic of prolactin in pregnant women during pregnancy.

Fig 2

Legend: NS: not significant; V: visit. Code: *: <0.05; **: <0.01; ***: <0.001; ****: <0.0001. 30μl of plasma was used to determine the concentration of prolactin in blood (ng/ml). Prolactin levels were compared between multigravidae and primigravidae at each scheduled visits as described in “Method” section and presented as box and whisker plots illustration: top, bottom and middle of box, representing 25th, 75th and 50th percentiles, respectively. In multigravidae, the prolactin concentration increase from V1 (enrolment) to V4 (delivery) before decreasing at V5. For primigravidae, this concentration increase from V1 to V3 before decreasing at V4 and V5.

At delivery, prolactin concentration measured in umbilical cord blood (529.0n g/ml [386.3–712.7]) was significantly higher (p = 0.001) than the concentration in peripheral blood collected during labour (324.6 ng/ml [206.6–375.2]) (Table 2). However when stratified by gravidity, the differences were not statistically significant either for peripheral blood (primigravidae 269.2 ng/ml [181.2–346.9]; multigravidae 364.7 ng/ml [261.5–436.9]; p = 0.160) or for umbilical cord blood (primigravidae 543.7 [386.3–853.1]; multigravidae 510.2 ng/ml [410.2–566.4] p = 0.529) (Table 3).

Cortisol and prolactin concentration in non-pregnant women

The cortisol and prolactin concentrations in non-pregnant women are summarised on Table 4. Nulliparous had higher cortisol (104.6 ng/ml [82.8–122.4]) and prolactin (16.7 ng/ml [15.5–25.4]) concentrations than primiparous/multiparous (cortisol 85.0 [72.7–99.5]; prolactin 9.1 [6.84–13.3]). Statistical analysis showed that the difference was significant for prolactin (p < 0.001) but not for cortisol (p = 0.095) (Table 4). The average concentration of these hormones was higher in pregnant women (cortisol 162.9ng/ml [127.3–190.5]; prolactin 324.6ng/ml [206.6–375.2]) than in non-pregnant women (cortisol 89.5ng/l [76.8–107.4]; prolactin 14.3ng/ml [8.9–16.7]) (see Figs 1 and 2, Tables 2 and 4). At week 6–7 after delivery, the concentration of prolactin remained much higher in pregnant women (205.5ng/ml [116.5–281.0]) than non-pregnant women (14.3 [8.9, 16.7]) (see Fig 2 and Table 4). However for cortisol, the concentration was higher in non-pregnant women (89.5ng/ml [76.8,– 107.4]) than in pregnant women (66.4ng/ml [47.9–96.5]) (see Fig 1 and Table 4).

Table 4. Cortisol and prolactin concentration in non-pregnant women.

Primiparous/Multiparous Nulliparous Overall P-value
Prolactin (ng/ml) [IQR] 9.1 [6.84, 13.3] 16.7 [15.52, 25.4] 14.3 [8.9, 16.7] <0.001
Cortisol (ng/ml) [IQR] 85.7 [72.73, 99.5] 104.6 [82.83, 122.4] 89.5 [76.8, 107.4] 0.095

Table 4 report the concentration of cortisol and prolactin in primiparous/multiparous and nulliparous. The difference was only statistically different for prolactin.

Interplay or variation between the cortisol and prolactin during follow-up

To assess the interplay between cortisol and prolactin during the follow-up, the variation of both hormones has been adjusted by gestation age, malaria infection and the correlation of the data have been also considered. The analysis showed that the average concentration of cortisol decreases by -0.04 ng/ml (95%CI -0.08 –-0.01) compared to the baseline concentration (117.7 ng/ml, 95%CI 85.44–150.01) when the concentration of prolactin increases by one unit (1.0 ng/ml) (p = 0.009) (Table 5). However, when the concentration of cortisol increases by one unit (1.0 ng/ml), the average concentration of prolactin decreases by -1.16 ng/ml (95%CI -2.07 –-0.25) compared to the baseline concentration (355.5 ng/ml, 95%CI 191.14–519.88) (p = 0.013) (Table 6).

Table 5. Interplay or correlation of prolactin on cortisol during pregnancy.

Predictors Cortisol
Estimates 95% CI p
(Intercept) 117.72 85.44–150.01 <0.001
Prolactin -0.04 -0.08 –-0.01 0.009
Primigravidae 12.36 -2.34–27.07 0.099
Positive malaria microscopy -3.15 -17.94–11.65 0.675

Table 5 report the correlation of prolactin on cortisol and seems that the increase of the increase of prolactin of one unit (1.0 ng/ml), the concentration of cortisol decrease by 0.04 ng/ml.

Table 6. Interplay or correlation of cortisol on prolactin during pregnancy.

Predictors Prolactin
Estimates 95% CI p
(Intercept) 355.51 191.14–519.88 <0.001
Cortisol -1.16 -2.07 –-0.25 0.013
Primigravidae -3.48 -80.59–73.63 0.929
Positive malaria microscopy 32.39 -45.82–110.59 0.414

Table 6 report the correlation of cortisol on prolactin and seems that the increase of the increase of cortisol of one unit (1.0 ng/ml), the concentration of prolactin decrease by -3.15 ng/ml.

The gravidity was associated to the decrease of prolactin (-3.48ng/ml, 95%CI -2.07 –-0.25) (Table 5) and the increase of cortisol (12.36ng/ml, 95%CI -2.34–27.07) in primigravidae compared to multigravidae, but the difference was not statistically significant (p = 0.099) (Table 6).

Gestational age and malaria infection

The proportion of asymptomatic P. falciparum malaria at baseline (visit 1) in pregnant women was 57.70% (15/26) versus 11.11% (3/27) in non-pregnant women. No case of symptomatic malaria was reported during the study. The geometric median parasite was 1,628 parasite/μl (range: 111–47,802). Among pregnant women, asymptomatic malaria infection in primigravidae was two-times higher than in multigravidae (10/13 versus 5/15, p = 0.02) at enrolment (visit 1: 16th-20th weeks) with a geometric median parasite of 1,725 parasites/μl (range: 111–47,802) and 1,628 parasites/μl (range: 216–5,282) for primigravidae and multigravidae, respectively. In non-pregnant women, only the nulliparous were infected (3/15) with a geometric median parasite of 471 parasites/μl (range: 158–537). During the scheduled visits, the prevalence decreased among pregnant women. At visit 3 (32th±1 weeks of pregnancy), malaria infection was detected only in 2 primigravidae women and none in multigravidae and inversely at visit 4 (2 infected in multigravidae and none in primigravidae) (Table 7). Moreover, malaria infection concurrently leads to an increase of the average concentration of prolactin (32.4 ng/ml; 95% CI: -45.82–110.59; p = 0.414) and a decrease of cortisol (-3.2 ng/ml; 95% CI: -17 .94–11.65; p = 0.675), though these changes were not statistically significant (Tables 5 and 6).

Table 7. Malaria infection by gestation and gestational age.

Geometric median parasite density
/μl (range: lower–upper)
Visits Primigravidae Multigravidae
    V1 (16–20 weeks) 1,725 (111–47,802) 1628 (216–5,282)
    V2 (28±1 weeks) 5,619 (-) 2,725 (-)
    V3 (32±1 weeks) 4,297 (793–7,801) -
    V4 (delivery) - 1,390 (736–2,044)
V5 (6–7 weeks after delivery) 80 (-) 56 (-)

Table 7 reported high geometrical median parasite density in primigravidae than multigravidae.

4. Discussion

Our study showed a significant progressive increase of cortisol concentration, with the highest concentrations reported in primigravidae compared to multigravidae. Although this progressive increase was not significant for prolactin, a “downward regulation effect” has been reported between both hormones. These findings show that the variation of these hormones during pregnancy are related to the gestational age. Indeed, a first pregnancy is a new experience for women that could have a psychological impact on the future mother [35]. However, cortisol and prolactin are often up-regulated in a context of stress [3638], with very different immunological functions: cortisol being an inhibitor of immune system [3941] and prolactin a stimulator [42, 43]. The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) reported in this study could also explain this antagonistic immunological function of both hormones. Moreover, this regulation despite the up regulation of both hormones can also explains the limits of the concept of “suppression of immune response” during pregnancy. The increase of prolactin and cortisol levels during pregnancy with the high impact of down regulation of cortisol on prolactin compared to prolactin on cortisol, suggests that sustained increase of cortisol concentration can explain the increased susceptibility of pregnant women, particularly in primigravidae who live in malaria endemic areas, but not suppression of immune response [34] as highlighted previously. This is not the case in the present study where despite the increase in cortisol level, malaria positivity decreased. This can be due to the intermittent preventive treatment (IPTp) given to all the pregnant women during antenatal consultation. Nevertheless, the psychological impact of the first pregnancy could partly explain the higher production of cortisol and prolactin in primigravida compared to multigravida as well as the higher prevalence of malaria at enrolment. In addition to stress, which upregulates cortisol production during pregnancy, the placenta also produces corticotropin which, appears to be autonomous and not subject to the normal feedback control of glucocorticoids [44, 45]. As for prolactin, its gradual increase during pregnancy is necessary and could be explained by the body’s need to maintain immune competence. Although the role of cortisol and prolactin in the reaction of the immune system has not been addressed, the graduate increase in the two hormones (with concentrations of prolactin higher than cortisol) during pregnancy could be explained by the need for the maternal body to regulate its immune response to create a favourable environment for a successful pregnancy. Other factors such as gluconeogenesis [46, 47] and preparation of the mammary glands for breastfeeding [48] could also explain the increase in cortisol and prolactin during pregnancy and the reported differences between the two groups.

Childbirth is a time of stress, both for the mother and for the future baby. The relationship between high concentrations of cortisol and prolactin at delivery has already been reported by Bouyou-Akotet et al. in 2005 [34]. This could explain the vulnerability of primigravidae to infections such as placental malaria approaching childbirth compared to multigravidae, which represent a risk for the foetus in primigravidae. Hypercortisolaemia at childbirth is thought to be influenced by factors such as pain-related anxiety and distress [49]. Thus, vaginal delivery is the most stressful, as indicated by high levels of cortisol circulating in the peripheral blood. The decrease in prolactin at childbirth has been reported previously [50, 51]. However, the reasons for this decline are divergent. Some authors believe that it is linked to unknown factors that inhibit the release of prolactin naturally stimulated by labour stress [51], while other authors evoke the idea of a non-response of the decidual tissue to stress due to labour [50]. In our study, the reasons of the decline of prolactin only observed in primigravidae have not been assessed. However, this could be due to the psychological impact of the first pregnancy on the hypothalamic mechanisms involved in its production [35, 52, 53]. However, additional researches are needed to validate this hypothesis in primigravida during childbirth. Our study showed a significant increase of prolactin and a significant decrease of cortisol in umbilical cord blood compared to peripheral blood during labour. This may be due to the placenta/decidual tissue [54]. Indeed, placental hormones include members of prolactin and growth hormone family [55]. The high concentrations of prolactin and cortisol observed in umbilical cord blood at delivery are likely to be placental origin. Nevertheless, their role in the development of new-born immunity and the prevention to infectious disease such as malaria during the first year of life remains unclear.

After childbirth and the expulsion of the placenta, the cortisol level returns to the pre-pregnancy level, while the prolactin level remains high. The decrease in cortisol is due to the absence of the placenta and the decrease of stress-associated childbirth, which are the main source of corticotrophin under the action of a permanent positive feedback and the resumption of control by the hypothalamic-pituitary axis. The high levels of prolactin could be explained by the sucking of the baby during breastfeeding, which then becomes the main stimulus that induces the secretion of prolactin by the lactotroph cells of the anterior pituitary after birth [56]. The high postpartum prolactin level promotes the stabilization and maintenance of milk synthesis [57]. Lactational hyperprolactinemia also prevents early postpartum pregnancy.

This is an explorative study conducted in pregnant women. However, this did not affect the findings of the present study, but allowed to lay the basis for future investigation of the roles of these endocrine hormones in immune system during pregnancy. A possible limitation is the enrolment period of pregnant and non-pregnant women. This could affect the expected results given the fact that malaria transmission in the study area was seasonal.

5. Conclusion

These findings showed that the concentrations of cortisol and prolactin throughout pregnancy were up-regulated by gestation except for primigravidae pregnant women for whom this hormone decreases at delivery and cortisol between the visits 2 and 3. A downward regulation effect between the two hormones was also reported, which seems to be important for both foetus and mother.

Supporting information

S1 Checklist. STROBE statement—Checklist of items that should be included in reports of cohort studies.

(DOCX)

pone.0310372.s001.docx (33.1KB, docx)
S1 Table. Concentration of cortisol and prolactin at scheduled visit and delivered.

This table summarize the value of cortisol and prolactin at scheduled visit.

(DOCX)

pone.0310372.s002.docx (14.8KB, docx)
S1 Data

(XLSX)

pone.0310372.s003.xlsx (18.7KB, xlsx)

Acknowledgments

We would like to thank the study staff of the rural health facilities of Nanoro, Seguedin and Nazoanga in the Health District of Nanoro for their valuable contributions to the work. We are indebted to the pregnant and non-pregnant women for their participation in the study.

Abbreviations

ANC

antenatal consultation

CRUN

Clinical Research Unit of Nanoro

EDTA

Ethylene diamine tetra acetic acid

IPT

immunologic pregnancy test

LMER

linear mixed-effects regression

NK

Natural Killer

SSA

sub-Saharan Africa

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

International Society for Infectious Diseases (ISID), Small Grant 2014, “Determination of cytotoxicity of NK cells against erythrocytes infected by Plasmodium Falciparum during pregnancy”. the funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.NG SC, Gilman-sachs A, Beaman KD, Beer AE, Kwak-kim J. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. American Journal of Reproductive Immunology. 2002;48(2):77–86. doi: 10.1034/j.1600-0897.2002.01105.x [DOI] [PubMed] [Google Scholar]
  • 2.Kwak-Kim JYH, Gilman-Sachs A, Kim CE. T Helper 1 and 2 Immune Responses in Relationship to Pregnancy, Nonpregnancy, Recurrent Spontaneous Abortions and Infertility of Repeated Implantation Failures. In: Immunology of Gametes and Embryo Implantation. Basel: KARGER; 2005. p. 64–79. [DOI] [PubMed] [Google Scholar]
  • 3.Rukavina D, Podack ER. Abundant perforin expression at the maternal-fetal interface: Guarding the semiallogeneic transplant. Vol. 21, Immunology Today. 2000. doi: 10.1016/s0167-5699(00)01603-0 [DOI] [PubMed] [Google Scholar]
  • 4.Mellor AL, Munn DH. Immunology at the maternal-fetal interface: Lessons for T cell tolerance and suppression. Vol. 18, Annual Review of Immunology. 2000. doi: 10.1146/annurev.immunol.18.1.367 [DOI] [PubMed] [Google Scholar]
  • 5.Szekeres-Bartho J, Barakonyi A, Miko E, Polgar B, Palkovics T. The role ofγ / δT cells in the feto-maternal relationship. Semin Immunol. 2001. Aug;13(4):229–33. [DOI] [PubMed] [Google Scholar]
  • 6.Meeusen ENT, Bischof RJ, Lee CS. Comparative T-cell responses during pregnancy in large animals and humans. Vol. 46, American Journal of Reproductive Immunology. 2001. doi: 10.1111/j.8755-8920.2001.460208.x [DOI] [PubMed] [Google Scholar]
  • 7.Gaunt G, Ramin K. Immunological tolerance of the human fetus. Vol. 18, American Journal of Perinatology. 2001. doi: 10.1055/s-2001-17861 [DOI] [PubMed] [Google Scholar]
  • 8.Vacchio MS, Jiang SP. The fetus and the maternal immune system: Pregnancy as a model to study peripheral T-cell tolerance. Vol. 19, Critical Reviews in Immunology. 1999. [PubMed] [Google Scholar]
  • 9.Menendez C. Malaria during pregnancy: Priority areas for current research on malaria during pregnancy. Vol. 93, Ann Trop Med Parasitol. 1999. p. S71–4. [DOI] [PubMed] [Google Scholar]
  • 10.Mor G, Cardenas I. The Immune System in Pregnancy: A Unique Complexity. American Journal of Reproductive Immunology. 2010. Mar 29;63(6):425–33. doi: 10.1111/j.1600-0897.2010.00836.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kareva I. Immune Suppression in Pregnancy and Cancer: Parallels and Insights. Transl Oncol. 2020. Jul;13(7):100759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Vol. 14, Immunology Today. 1993. doi: 10.1016/0167-5699(93)90235-D [DOI] [PubMed] [Google Scholar]
  • 13.Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res. 2012. Dec 24;54(1–3):254–61. doi: 10.1007/s12026-012-8303-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011. Mar 14;1221(1):80–7. doi: 10.1111/j.1749-6632.2010.05938.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Svensson-arvelund J, Mehta RB, Lindau R, Mirrasekhian E, Rodriguez-martinez H, Lash GE, et al. The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. The Journal of Immunology. 2015;194(4):1534–44. doi: 10.4049/jimmunol.1401536 [DOI] [PubMed] [Google Scholar]
  • 16.Smith R, Mesiano S, Chan E-C, Brown S, Jaffe RB. Corticotropin-Releasing Hormone Directly and Preferentially Stimulates Dehydroepiandrosterone Sulfate Secretion by Human Fetal Adrenal Cortical Cells*. J Clin Endocrinol Metab. 1998. Aug 1;83(8):2916–20. doi: 10.1210/jcem.83.8.5020 [DOI] [PubMed] [Google Scholar]
  • 17.Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus. Endocr Rev. 2006. Apr 1;27(2):141–69. doi: 10.1210/er.2005-0011 [DOI] [PubMed] [Google Scholar]
  • 18.Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: Structure, Function, and Regulation of Secretion. Physiol Rev. 2000. Jan 10;80(4):1523–631. doi: 10.1152/physrev.2000.80.4.1523 [DOI] [PubMed] [Google Scholar]
  • 19.Berczi I, Chalmers IM, Nagy E, Warrington RJ. The immune effects of neuropeptides. Vol. 10, Bailliere’s Clinical Rheumatology. 1996. p. 227–57. doi: 10.1016/s0950-3579(96)80016-1 [DOI] [PubMed] [Google Scholar]
  • 20.Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Vol. 62, Hormones and Behavior. 2012. doi: 10.1016/j.yhbeh.2012.02.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Dhabhar FS. Enhancing versus Suppressive Effects of Stress on Immune Function: Implications for Immunoprotection and Immunopathology. Neuroimmunomodulation. 2009;16(5):300–17. doi: 10.1159/000216188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014. May 6;58(2–3):193–210. doi: 10.1007/s12026-014-8517-0 [DOI] [PubMed] [Google Scholar]
  • 23.Bouyou-Akotet MK, Issifou S, Meye JF, Kombila M, Ngou-Milama E, Luty a JF, et al. Depressed natural killer cell cytotoxicity against Plasmodium falciparum- infected erythrocytes during first pregnancies. Clinical Infectious Diseases. 2004;38(3):342–7. doi: 10.1086/380646 [DOI] [PubMed] [Google Scholar]
  • 24.Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. Journal of Clinical Endocrinology and Metabolism. 2011;96(5). doi: 10.1210/jc.2010-2395 [DOI] [PubMed] [Google Scholar]
  • 25.Bouyou-Akotet MK, Mavoungou E. Natural killer cell IFN-γ-activity is associated with Plasmodium falciparum infection during pregnancy. Exp Parasitol. 2009;123(3). [DOI] [PubMed] [Google Scholar]
  • 26.Seckl JR. 11β-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol. 2004. Dec;4(6):597–602. [DOI] [PubMed] [Google Scholar]
  • 27.Dong J, Qu Y, Li J, Cui L, Wang Y, Lin J, et al. Cortisol inhibits NF-κB and MAPK pathways in LPS activated bovine endometrial epithelial cells. Int Immunopharmacol. 2018. Mar;56:71–7. [DOI] [PubMed] [Google Scholar]
  • 28.Clevenger C V., Furth PA, Hankinson SE, Schuler LA. The Role of Prolactin in Mammary Carcinoma. Endocr Rev. 2003. Feb 1;24(1):1–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? Journal of Endocrinology. 2011. Feb 1;208(2):107–17. doi: 10.1677/JOE-10-0076 [DOI] [PubMed] [Google Scholar]
  • 30.Tripathi A, Sodhi A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. Int Immunol. 2008. Mar;20(3):327–36. doi: 10.1093/intimm/dxm145 [DOI] [PubMed] [Google Scholar]
  • 31.Bleker LS, Roseboom TJ, Vrijkotte TG, Reynolds RM, de Rooij SR. Determinants of cortisol during pregnancy–The ABCD cohort. Psychoneuroendocrinology. 2017;83. doi: 10.1016/j.psyneuen.2017.05.026 [DOI] [PubMed] [Google Scholar]
  • 32.Vleugels MPH, Brabin B, Eling WMC, de Graaf R. Cortisol and plasmodium falciparum infection in pregnant women in kenya. Trans R Soc Trop Med Hyg. 1989;83(2). doi: 10.1016/0035-9203(89)90632-9 [DOI] [PubMed] [Google Scholar]
  • 33.VLEUGELS MPH, ELING WMC, ROLLAND R, de GRAAF R. Cortisol and loss of malaria immunity in human pregnancy. BJOG. 1987;94(8). doi: 10.1111/j.1471-0528.1987.tb03722.x [DOI] [PubMed] [Google Scholar]
  • 34.Bouyou-Akotet MK, Adegnika AA, Agnandji ST, Ngou-Milama E, Kombila M, Kremsner PG, et al. Cortisol and susceptibility to malaria during pregnancy. Microbes Infect. 2005;7(11–12). doi: 10.1016/j.micinf.2005.04.008 [DOI] [PubMed] [Google Scholar]
  • 35.Jaju S, al Kharusi L, Gowri V. Antenatal prevalence of fear associated with childbirth and depressed mood in primigravid women. Indian J Psychiatry. 2015;57(2). doi: 10.4103/0019-5545.158152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Carroll BJ. Neuroendocrine Regulation in Depression. Arch Gen Psychiatry. 1976;33(9). [DOI] [PubMed] [Google Scholar]
  • 37.LINKOWSKI P, MENDLEWICZ J, LECLERCQ R, BRASSEUR M, HUBAIN P, GOLSTEIN J, et al. The 24-Hour Profile of Adrenocorticotropin and Cortisol in Major Depressive Illness*. J Clin Endocrinol Metab. 1985;61(3). doi: 10.1210/jcem-61-3-429 [DOI] [PubMed] [Google Scholar]
  • 38.Linkowski P, Spiegel K, Kerkhofs M, L’Hermite-Balériaux M, van Onderbergen A, Leproult R, et al. Genetic and environmental influences on prolactin secretion during wake and during sleep. Am J Physiol Endocrinol Metab. 1998;274(5 37–5). doi: 10.1152/ajpendo.1998.274.5.E909 [DOI] [PubMed] [Google Scholar]
  • 39.Callewaert DM, Moudgil VK, Radcliff G, Waite R. Hormone specific regulation of natural killer cells by cortisol Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation. FEBS Lett. 1991;285(1):108–10. [DOI] [PubMed] [Google Scholar]
  • 40.Zhou J, Olsen S, Moldovan J, Fu X, Sarkar FH, Moudgil VK, et al. Glucocorticoid regulation of natural cytotoxicity: Effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Cell Immunol. 1997;178(2). doi: 10.1006/cimm.1997.1138 [DOI] [PubMed] [Google Scholar]
  • 41.Gatti G, Cavallo R, Sartori ML, del Ponte D, Masera R, Salvadori a, et al. Inhibition by cortisol of human natural killer (NK) cell activity. J Steroid Biochem. 1987;26(1):49–58. doi: 10.1016/0022-4731(87)90030-6 [DOI] [PubMed] [Google Scholar]
  • 42.Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh). 1983;102(3). doi: 10.1530/acta.0.1020351 [DOI] [PubMed] [Google Scholar]
  • 43.Jara LJ, Lavalle C, Fraga A, Gómez-Sanchez C, Silveira LH, Martinez-Osuna P, et al. Prolactin, immunoregulation, and autoimmune diseases. Semin Arthritis Rheum. 1991;20(5). doi: 10.1016/0049-0172(91)90028-x [DOI] [PubMed] [Google Scholar]
  • 44.Challis J, Newnham J, Petraglia F, Yeganegi M, Bocking A. Fetal sex and preterm birth. In: Placenta. 2013. doi: 10.1016/j.placenta.2012.11.007 [DOI] [PubMed] [Google Scholar]
  • 45.Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: Challenges in disease detection and treatment. Vol. 26, Endocrine Reviews. 2005. doi: 10.1210/er.2004-0025 [DOI] [PubMed] [Google Scholar]
  • 46.Akinloye O, Obikoya OM, Jegede AI, Oparinde DP, Arowojolu AO. Cortisol plays central role in biochemical changes during pregnancy. International Journal of Medicine and Biomedical Research. 2013; [Google Scholar]
  • 47.Tayek JA, Katz J. Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: Relationship to serum cortisol. Am J Physiol Endocrinol Metab. 1997;272(3 35–3). doi: 10.1152/ajpendo.1997.272.3.E476 [DOI] [PubMed] [Google Scholar]
  • 48.Macias H, Hinck L. Mammary gland development. Vol. 1, Wiley Interdisciplinary Reviews: Developmental Biology. 2012. doi: 10.1002/wdev.35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Shelton MM, Schminkey DL, Groer MW. Relationships Among Prenatal Depression, Plasma Cortisol, and Inflammatory Cytokines. Biol Res Nurs. 2015;17(3). doi: 10.1177/1099800414543821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lao TT, Panesar NS. The effect of labour on prolactin and cortisol concentrations in the mother and the fetus. European Journal of Obstetrics and Gynecology and Reproductive Biology. 1989;30(3). doi: 10.1016/0028-2243(89)90006-3 [DOI] [PubMed] [Google Scholar]
  • 51.Yaginuma T. Decrease or increase in maternal blood prolactin concentrations during labor. Acta Obstet Gynaecol Jpn. 1982;34(1). [PubMed] [Google Scholar]
  • 52.Grattan DR, le Tissier P. Hypothalamic Control of Prolactin Secretion, and the Multiple Reproductive Functions of Prolactin. In: Knobil and Neill’s Physiology of Reproduction: Two-Volume Set. 2015. [Google Scholar]
  • 53.Voogt JL, Lee Y, Yang S, Arbogast L. Chapter 12 Regulation of prolactin secretion during pregnancy and lactation. In 2001. p. 173–85. [DOI] [PubMed] [Google Scholar]
  • 54.Kimball CD, Chang CM, Huang SM, Houck JC. Immunoreactive endorphin peptides and prolactin in umbilical vein and maternal blood. Am J Obstet Gynecol. 1981;140(2). doi: 10.1016/0002-9378(81)90103-4 [DOI] [PubMed] [Google Scholar]
  • 55.Napso T, Yong HEJ, Lopez-Tello J, Sferruzzi-Perri AN. The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation. Vol. 9, Frontiers in Physiology. 2018. doi: 10.3389/fphys.2018.01091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Zhang F, Xia H, Shen M, Li X, Qin L, Gu H, et al. Are Prolactin Levels Linked to Suction Pressure? Breastfeeding Medicine. 2016;11(9). doi: 10.1089/bfm.2015.0083 [DOI] [PubMed] [Google Scholar]
  • 57.Hill PD, Aldag JC, Demirtas H, Naeem V, Parker NP, Zinaman MJ, et al. Association of serum prolactin and oxytocin with milk production in mothers of preterm and term infants. Biol Res Nurs. 2009;10(4). doi: 10.1177/1099800409331394 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Ibrahim Sebutu Bello

31 Jan 2024

PONE-D-23-33355Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic areaPLOS ONE

Dear Dr. Kiemde,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

============================================================

Please submit your revised manuscript by Mar 16 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ibrahim Sebutu Bello, MBBS, MPH, MD, FMCGP

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. Thank you for stating the following financial disclosure: "International Society for Infectious Diseases (ISID), Small Grant 2014, “Determination of cytotoxicity of NK cells against erythrocytes infected by Plasmodium Falciparum during pregnancy”."

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. We note that your Data Availability Statement is currently as follows: All relevant data are within the paper.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

5. We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

6. We notice that your supplementary tables are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript investigates the effect of gestation on cortisol and prolactin levels in pregnant women, comparing primigravidae and multigravidae. The study design, methodology, and data analysis are well-described, and the results are presented clearly and concisely. The discussion adequately interprets the findings in the context of existing literature.

Major Comments:

1. Background:

o The introduction could be strengthened by providing a more focused review of the role of cortisol and prolactin in pregnant women, particularly in relation to immune function and stress response.

o The concept of "suppression of (some) immune responses" could be further elaborated upon, differentiating between specific types of immune responses and the nuances involved.

2. Methods:

o The inclusion and exclusion criteria for participants should be clearly stated, especially for the control groups.

o It would be helpful to explain the rationale behind the chosen time points for sample collection.

o The description of the laboratory procedures could be expanded to include details such as the manufacturers and specific kits used for the cortisol and prolactin assays.

3. Results:

o The tables and figures could be improved by adding more descriptive captions and legends.

o Consider including statistical tests and p-values in the figures directly.

o It would be helpful to present the results of the correlation analysis between cortisol and prolactin in a separate table.

4. Discussion:

o The discussion could be strengthened by addressing limitations of the study, such as the relatively small sample size and potential confounding factors.

o Consider including more references to support the claims made about the roles of cortisol and prolactin in pregnancy.

Minor Comments:

• Consider using a consistent formatting style for references throughout the manuscript.

• Ensure that all abbreviations are defined upon first use.

• Check for typos and grammatical errors.

Specific Points:

• Page 5: Define IPT (immunologic pregnancy test).

• Page 6: Explain how the detection limit of 100 ng/ml for prolactin was adjusted for higher concentrations.

• Page 7: Clarify what is meant by "non-response" in the sample size calculation.

• Page 7: Mention the statistical test used for comparing cortisol and prolactin concentrations between gravidity groups.

• Page 7: Specify the factors included in the LMER model for assessing the interplay between cortisol and prolactin.

Overall, the manuscript presents valuable data on the modulation of cortisol and prolactin levels during pregnancy. Addressing the major and minor comments will further strengthen the manuscript and improve its clarity and impact.

Reviewer #2: REVIEW COMMENTS

TITLE: Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic area

The study investigated a rather interesting and pertinent topic and the manuscript was generally well written. The specific issues that need to be addressed to improve the report are highlighted below. There are also some grammatical errors here and there that should be corrected eg. ”Primigravidae showed a higher increase of cortisol than multigravidae during pregnancy with statistically significant different(ce)”

Background

1. The first two paragraphs of the background do not appear to be relevant to the present manuscript but rather to the overall study. The background can start with the 3rd paragraph and then expanded a little bit.

Methods

2. The inclusion and exclusion criteria should be more explicit.

3. Were those with twin gestation excluded? Were women with malaria symptoms excluded, or there was no case of symptomatic malaria among those with positive tests? Only cases of asymptomatic malaria infection were mentioned in the result. This may need to be clarified. This information is more imperative considering that “Malaria, caused by Plasmodium falciparum, remains the first cause of medical consultation in pregnant women in this region…”

4. Were there any loss to follow-up or incomplete data??? If all the patients enrolled at baseline ended up completing the study. It is good to know what measures were made that ensured all respondents attended all follow-up visits, delivered at the facilities, and attended PNC.

5. Where and how were the controls recruited?

6. Sample size: the ideal way to adjust for 10% attrition is: Sample size / (1 – attrition rate)

7. Data analysis: a bit more detail would be in order. For example, which statistical test was used for the difference in quantitative variables between groups eg. hormone concentrations at delivery between babies and mothers (table 2), and between primigravidae and multigravidae (table 3), etc.

Results

8. Mode of delivery: was the mode of delivery the same (vaginal?) for all pregnant women? Did authors consider the possibility of the effect of the mode of delivery on the hormone concentration, especially cortisol, at V4-delivery?

9. Variation of cortisol during pregnancy: concerning the p-value of 0.024 in this sentence “Primigravidae showed a higher increase of cortisol than multigravidae during pregnancy with statistically significant different (p=0.024)” and also in figure 2, is it speaking to the difference in the increase between the two groups or the difference in the repeated measures across different visits for ALL pregnant respondents?

10. Variation of cortisol during pregnancy: “A gradual increase in cortisol concentrations from the enrolment to delivery was observed …with the highest concentrations measured at delivery…” This statement did not reflect the fact that there was no increase, but a decrease btw V2 and V3.

11. Variation of prolactin during pregnancy: Authors stated: “Nevertheless, the difference was not statistically significant during the follow-up (p=0.6).” Is this referring to the entire 6 visits? If that’s so, how does that juxtapose with the next statement starting with: “The (increase in??) concentration of prolactin was statistically significant from visit…”. If the latter was based on post-hoc analyses, it should be stated in the data analysis section, along with the specific statistical test used.

12. Figures 2&3: There is an indication that an ANOVA test was used for the analyses. Such information should be included in the data analysis section. However, considering the way the cortisol and prolactin concentrations were summarized and presented using the median, it suggests that they were NOT normally distributed (which can also be deduced from the box plots), hence a non-parametric alternative to repeated measure ANOVA may be more appropriate.

13. In all relevant tables, I suggest that Q1-Q3 be replaced with IQR, to synchronise with the way it was represented in the main text

14. Table 3: Some p-values are incorrectly written, have commas

15. Table 3: Kindly crosscheck the title, seems should be “Stratification….by gravidity….”

16. In all relevant tables, I suggest that Q1-Q3 be replaced with IQR, to synchronise with the way it was represented in the main text

17. Table 3: Some p-values are incorrectly written, have commas

18. Table 3: Kindly crosscheck the title, seems should be “Stratification….by gravidity….”

Discussion

19. In the study, while cortisol increased with GA, malaria positivity decreased. Hence, the following statement does not seem to be completely supported by the study findings: “The increase of prolactin and cortisol levels during pregnancy with the high impact of down regulation of cortisol on prolactin compared to prolactin on cortisol suggests that sustained increase of cortisol concentration can explain the increased susceptibility of pregnant women, particularly in primigravidae who live in malaria endemic areas”.

20. Conclusion: This needs to be revised for the following reasons:

a) The statement “…except for primigravidae pregnant women for whom this hormone decreases at delivery” is not true for cortisol”.

b) I have concerns about the conclusion of a ‘negative correlation’ based on the interpretation of the results. Negative correlation suggests that they were moving in the opposite direction i.e. while one was increasing, the other was decreasing. It seems to me that the interpretation should rather be that the rate or pattern of increase was different for both hormones i.e. the rate was higher for one than for the other, because to a large extent, both increased from baseline.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Abhilasha Sharma

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: comments.docx

pone.0310372.s004.docx (14.5KB, docx)
PLoS One. 2024 Nov 4;19(11):e0310372. doi: 10.1371/journal.pone.0310372.r002

Author response to Decision Letter 0


25 Mar 2024

REBUTTAL TO THE POINTS RAISED BY Editor:

Comment 1: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

RESPONSE: We would like to thank the editor for this observation. Now we are made the changes to meet the PLOS ONE’s style requirement.

Comment 2: Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

RESPONSE: Thank to the editor to remind us about the advantage of depository data in our research career. We are planned to deposit this database on repository as soon as the main data are published.

Comment 3: Thank you for stating the following financial disclosure: "International Society for Infectious Diseases (ISID), Small Grant 2014, “Determination of cytotoxicity of NK cells against erythrocytes infected by Plasmodium Falciparum during pregnancy”."

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

RESPONSE: Now we mentioned the role of the funder in the project in the cover letter above. Please note that the funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Comment 4: We note that your Data Availability Statement is currently as follows: All relevant data are within the paper.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

RESPONSE: Thank to the editor to pointed this out. As mentioned above, all relevant data are within the paper. However, the data that support the findings of this study are available on request from the corresponding author, FK. The data are not publicly available due as their containing information that could compromise the privacy of research participants. Please you can go ahead and change the online submission form on my behalf.

Comment 5: We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

RESPONSE: The figure 1 has been deleted to the manuscript and the manuscript has been updated. Thank.

Comment 6: We notice that your supplementary tables are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list..

RESPONSE: The supplement table has been remove to the manuscript and uploaded as “Supporting information”. It has been also renamed as “Supporting table”.

REBUTTAL TO THE POINTS RAISED BY REVIEWERS:

Reviewer #1

Comment 1: The manuscript investigates the effect of gestation on cortisol and prolactin levels in pregnant women, comparing primigravidae and multigravidae. The study design, methodology, and data analysis are well-described, and the results are presented clearly and concisely. The discussion adequately interprets the findings in the context of existing literature.

RESPONSE: We would like to thank the reviewer for his/her positive appreciation of the manuscript.

Major comments

1. Background

Comment 2: The introduction could be strengthened by providing a more focused review of the role of cortisol and prolactin in pregnant women, particularly in relation to immune function and stress response.

RESPONSE: We have now strengthened the introduction by providing a more focus review in the role: line 115 – 117: “This is the case of stress responses on immune system during pregnancy. Indeed, the immune stress can be bidirectional by enhancing or suppress immune function [21,22]”.

Comment 3: The concept of "suppression of (some) immune responses" could be further elaborated upon, differentiating between specific types of immune responses and the nuances involved.

RESPONSE: We have now reviewed the concept of “suppression of (some) immune response” and updated the references list: line 100 – 102: “Studies consider immunosuppression as a state in which immune system does not work as well it should. This mechanism provided to mother an effective protection from harmful pathogens while allowing tolerance to foetal antigens [13,14]”.

Methods

Comment 4: The inclusion and exclusion criteria for participants should be clearly stated, especially for the control groups.

RESPONSE: We have now reviewed the inclusion criteria for the control arm: line 177 – 183: “For the control groups, participants were recruitment within the catchment area of the recruitment health facilities listed above. In this group, participants included were non-pregnant nulliparous and both primiparous/ multiparous individuals. The number of nulliparous and primiparous/multiparous to be recruited by health facility catchment area were paired respectively to the number of primigravidae and multigravidae women recruited in this health facility catchment area. For each participant enrolled in the control group, venous blood was drawn once into EDTA tubes”.

Comment 5: It would be helpful to explain the rationale behind the chosen time points for sample collection.

RESPONSE: We have now explained the rationale behind the chosen time points for the sample collection: line 169 – 173: “Regarding the rationale behind these time points, the choice of 16th to 20th weeks of pregnancy is related to the fact that pregnant women consult to their first antenatal consultation at this period, due to socio-economic factors. This also represent the end of organogenesis. The choices of 28th�1 weeks of pregnancy is related to the maturation of the different organs of the foetus and 32th �1 to the pre-delivery”.

Comment 6: The description of the laboratory procedures could be expanded to include details such as the manufacturers and specific kits used for the cortisol and prolactin assays.

RESPONSE: With respect to the review related to this comment, we would like to refer to line 218 – 228: “Plasma concentrations of cortisol and prolactin were determined by using the test device ichromaTM cortisol for the quantification of cortisol and ichromaTM prolactin for the quantification of prolactin on the devices i-chamber (Weldon Biotech India Pvt. Ltd. India) and ichroma II (Boditech Med Inc. Korea) according to the procedure described by the manufacturer. For the quantification of the cortisol, 30µl of plasma were transferred to the tube containing the detection buffer provided by the manufacturer and mixed 10 times manually by pipetting. A volume of 75µl of the mixture were placed in the well of the ichromaTM cortisol cartridge and immediately incubated at 25°C for 10 minutes in the i-chamber. After incubation, the cartridge was removed and read immediately in the ichroma II. The analyzer automatically displayed the test result on the display screen, printed and validated. The procedure of quantification of prolactin was similar to cortisol, except the volume of plasma pipetted (75µl instead of 30µl)”. The details on manufacturers and cortisol and prolactin kits were included.

Results

Comment 7: The tables and figures could be improved by adding more descriptive captions and legends.

RESPONSE: We have now added descriptive captions and legends for figures and tables.

Comment 8: Consider including statistical tests and p-values in the figures directly.

RESPONSE: We would like to thank the reviewer for this observation. We have now added p-values in the figure directly.

Comment 9: It would be helpful to present the results of the correlation analysis between cortisol and prolactin in a separate table.

RESPONSE: We now present the results of the correlation analysis between cortisol and prolactin in a separate table (see table 5 and 6) and the numbers of the tables has been updated.

Discussion

Comment 10: The discussion could be strengthened by addressing limitations of the study, such as the relatively small sample size and potential confounding factors.

RESPONSE: We would like to thank the reviewer for pointed-out the sample size. This has been already highlighted in the manuscript: line 477 – 482 : “This is an explorative study conducted in pregnant women. The study has been designed to determine the cytotoxicity of NK cells against erythrocytes infected by Plasmodium falciparum. However, this did not affect the findings of the present study, but allowed to lay the basis for future investigation of the roles of these endocrine hormones in immune system during pregnancy. A possible limitation is the enrolment period of pregnant and non-pregnant women. This could affect the expected results given the fact that malaria transmission in the study area was seasonal”. This cannot be reported as a limit given the fact that this was an explorative study and the findings need to be confirm with an important sample size.

Comment 11: Consider including more references to support the claims made about the roles of cortisol and prolactin in pregnancy.

RESPONSE: We have now including more references to support the claims made about the role of cortisol and prolactin.

Minor Comments:

Comment 12: Consider using a consistent formatting style for references throughout the manuscript.

RESPONSE: We have now using consistent formatting style for references. Thank.

Comment 13: Ensure that all abbreviations are defined upon first use.

RESPONSE: We would like to thank reviewer for this observation. We have now made correction and added abbreviation paragraph to the manuscript (see line 502 – 505).

Comment 14: Check for typos and grammatical errors.

RESPONSE: These are now checked.

Specific Points:

Comment 15: Page 5: Define IPT (immunologic pregnancy test).

RESPONSE: With respect to the review related to this comment, IPT was define: line 185.

Comment 16: Page 6: Explain how the detection limit of 100 ng/ml for prolactin was adjusted for higher concentrations.

RESPONSE: With respect to the review related to this comment, we would like to refer to line 229 – 234: “The detection limit of prolactin with ichroma II is 100ng/ml. In case of concentration over 100ng/ml, ¼ and 1�8 dilution of the plasma was done with saline phosphate buffer as recommended by the manufacturer. The exact value of the prolactin was then obtained by multiplying the measured value by the dilution factor”.

Comment 17: Page 7: Clarify what is meant by "non-response" in the sample size calculation.

RESPONSE: We have now clarified: Line 266: “By considering 10% o

Decision Letter 1

Ibrahim Sebutu Bello

24 May 2024

PONE-D-23-33355R1Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic areaPLOS ONE

Dear Dr. Kiemde,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

============================================================

Please submit your revised manuscript by Jul 08 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ibrahim Sebutu Bello, MBBS, MPH, MD, FMCGP

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Kindly provide a response to all the issues raised by the reviewer

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: Dear authors

Many thanks for your research

Here are some comments on your original research.

1. In line 208 and 209 “The detection limit of prolactin with ichroma II is 100ng/ml. In case of concentration over 100ng/ml, ¼ and 1�8 dilution of the plasma was done with saline phosphate buffer as recommended” the detection limit is an incorrect phrase. In clinical laboratory, we describe the detection limit as: the lowest concentration that the procedure (laboratory kit) can detect. The highest concentration that the procedure or kit can detect and higher concentrations should be diluted is defined as the linearity range. Therefore, dear authors should correct this definition. Please, refer to kit inset sheet/instruction about the linearity and detection limit complementary descriptions.

2. In figures 1 and 2 (box plots), please, correct the p-values decimals. Please, remove extra decimals.

3. In discussion section, I think “the first year of live” is better to be replaced with “the first year of life”.

4. In discussion section, Lines 411 and 412 “This is an explorative study conducted in pregnant women. The study has been designed to determine the cytotoxicity of NK cells against erythrocytes infected by Plasmodium falciparum.” This phrase is related to which study? If it is related to the current study, I can not see any direct variable related to NK cells and immune system. If this is not related to the current study, please remove it from discussion and abstract and elsewhere in body text.

Many thanks with the best wishes

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: Yes: Abdorrahim Absalan

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Nov 4;19(11):e0310372. doi: 10.1371/journal.pone.0310372.r004

Author response to Decision Letter 1


4 Jul 2024

REBUTTAL TO THE POINTS RAISED BY REVIEWERS:

Reviewer #2 (No response)

Reviewer #3

General comment: Dear authors, Many thanks for your research. Here are some comments on your original research.

RESPONSE: We would like to thank the reviewer for his/her time to review the resubmission of the manuscript. All the comments have been addressed in the review manuscript.

Comment 1: In line 208 and 209 “The detection limit of prolactin with ichroma II is 100ng/ml. In case of concentration over 100ng/ml, ¼ and 1�8 dilution of the plasma was done with saline phosphate buffer as recommended” the detection limit is an incorrect phrase. In clinical laboratory, we describe the detection limit as: the lowest concentration that the procedure (laboratory kit) can detect. The highest concentration that the procedure or kit can detect and higher concentrations should be diluted is defined as the linearity range. Therefore, dear authors should correct this definition. Please, refer to kit inset sheet/instruction about the linearity and detection limit complementary descriptions.

RESPONSE: We would like to thank the reviewer for this observation regarding the detection limit. We have now corrected the manuscript: line 208: “The threshold for prolactin quantification with ichroma II is 100ng/ml”.

Comment 2: In figures 1 and 2 (box plots), please, correct the p-values decimals. Please, remove extra decimals

RESPONSE: We would like to thank the reviewer for this observation. We have now arranged the p-values in the figure directly and add a legend to the figure.

Comment 3: In discussion section, I think “the first year of live” is better to be replaced with “the first year of life”.

RESPONSE: Now we are corrected. Please see line 401 – 403: “Nevertheless, their role in the development of new-born immunity and the prevention to infectious disease such as malaria during the first year of life remains unclear”.

Comment 4: In discussion section, Lines 411 and 412 “This is an explorative study conducted in pregnant women. The study has been designed to determine the cytotoxicity of NK cells against erythrocytes infected by Plasmodium falciparum.” This phrase is related to which study? If it is related to the current study, I can not see any direct variable related to NK cells and immune system. If this is not related to the current study, please remove it from discussion and abstract and elsewhere in body text. Many thanks with the best wishes

RESPONSE: We have now deleted the following sentence to the manuscript: “The study has been designed to determine the cytotoxicity of NK cells against erythrocytes infected by Plasmodium falciparum”.

Attachment

Submitted filename: Kiemde et al_Rebuttal_PONE-D-23-33355R1_29052024_Final.docx

pone.0310372.s005.docx (24.4KB, docx)

Decision Letter 2

Ibrahim Sebutu Bello

30 Aug 2024

Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic area

PONE-D-23-33355R2

Dear Dr. Kiemde,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ibrahim Sebutu Bello, MBBS, MPH, MD, FMCGP

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Ibrahim Sebutu Bello

3 Sep 2024

PONE-D-23-33355R2

PLOS ONE

Dear Dr. Kiemde,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ibrahim Sebutu Bello

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE statement—Checklist of items that should be included in reports of cohort studies.

    (DOCX)

    pone.0310372.s001.docx (33.1KB, docx)
    S1 Table. Concentration of cortisol and prolactin at scheduled visit and delivered.

    This table summarize the value of cortisol and prolactin at scheduled visit.

    (DOCX)

    pone.0310372.s002.docx (14.8KB, docx)
    S1 Data

    (XLSX)

    pone.0310372.s003.xlsx (18.7KB, xlsx)
    Attachment

    Submitted filename: comments.docx

    pone.0310372.s004.docx (14.5KB, docx)
    Attachment

    Submitted filename: Kiemde et al_Rebuttal_PONE-D-23-33355R1_29052024_Final.docx

    pone.0310372.s005.docx (24.4KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES